KLP Kapitalforvaltning AS Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

KLP Kapitalforvaltning AS purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,823 shares of the medical equipment provider’s stock, valued at approximately $1,505,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State of New Jersey Common Pension Fund D increased its position in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its stake in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 129 shares in the last quarter. Avantax Advisory Services Inc. increased its holdings in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 132 shares during the last quarter. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares in the last quarter. Finally, Aurora Investment Counsel lifted its holdings in shares of Lantheus by 0.8% during the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock worth $1,718,000 after acquiring an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $96.16 on Friday. The company has a market capitalization of $6.59 billion, a P/E ratio of 16.00 and a beta of 0.38. Lantheus Holdings, Inc. has a fifty-two week low of $58.16 and a fifty-two week high of $126.89. The stock has a 50 day moving average price of $93.21 and a two-hundred day moving average price of $96.44.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LNTH shares. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Buying and Selling

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 over the last ninety days. 1.50% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.